Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Eisai’s Half-Year Sales Grow on Global Brands, Profits Slide after EA Pharma One-Off Gain
Eisai enjoyed steady sales of global brands, such as cancer drugs Halaven (eribulin) and Lenvima (lenvatinib), in the April-September first half of FY2017, ringing up year-on-year growth in all regions, including Japan, the Americas, and China. In the six-month period,…
To read the full story
Related Article
- Eisai Chalks Up 1st Double-Digit Growth in 11 Years on Merck Deal, Global Brands
May 16, 2018
- Eisai CEO Sees 4 Global Brands as Drivers through FY2020
November 2, 2017
- Eisai Ups Profit Estimates for April-September
October 27, 2017
- Eisai’s Global Brands Brisk but Sales Slip on Forex, Drug Price Revision
May 11, 2017
BUSINESS
- FDA Accepts BridgeBio’s Infigratinib NDA for Achondroplasia
October 8, 2026
- Eylea 8 mg Shows Vision Gains in 24-Week Analysis
October 8, 2026
- Boehringer, Hiroshima Tie Up on Health Promotion
October 8, 2026
- Japan Ethical Drug Sales Up 3% in August: Crecon
October 8, 2026
- PeptiDream Earns Milestone Payment from US Merck
October 8, 2026
Japan’s plasma-derived product industry is approaching a turning point as the government prepares to step in with unprecedented support for…
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…